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Introduction
Idiopathic severe aplastic anemia (SAA) is an uncommon disease characterized by pancytopenia and hypocellular bone marrow. Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA) is the standard treatment for patients with SAA who do not have a human leukocyte antigen (HLA)-matched related donor; it leads to a response rate of 60 to 70% (1, 2) . Historically, in Europe and the United States, horse ATG has been used for first-line therapy and rabbit ATG has been used for relapsed patients or non-responders to horse ATG (3, 4) . Because horse ATG (Lymphoglobulin, Genzyme, Cambridge, MA, USA) was withdrawn from the market and replaced by rabbit ATG (Thymoglobulin, Genzyme), rabbit ATG has been prospectively evaluated as first-line IST in the United States and Europe (5, 6) . Both studies showed inferior results with a combination of rabbit ATG and CSA compared with horse ATG and CSA. However, follow-up periods were relatively short in both studies; the median follow-up was 839 days (range, 2 to 1,852 days) in the study from the National Institutes of Health (NIH) (5) and 397 days (range, 6 to 805 days) in the study from the European Blood and Marrow Transplant Group (EBMT) (6) .
In Asian countries, both horse ATG and rabbit ATG have been used as first-line IST since the early 1990s, which provides an opportunity to compare long-term outcomes of patients who received horse ATG or rabbit ATG. We retrospectively evaluated the outcome of 297 SAA patients who received horse ATG plus CSA and 158
SAA patients who received rabbit ATG plus CSA.
Methods
We analyzed data from 455 SAA patients who received IST with horse ATG plus CSA or rabbit ATG plus CSA in Japan, China, and Korea between 1992 and 2010. The outcome of 205 patients who received horse ATG and that of 40 children who received rabbit ATG were previously reported (7, 8) . Patients with idiopathic SAA were included in the study if they were younger than 18 years and received IST within 6 months after diagnosis without specific prior treatments. Severity of disease was classified according to currently used criteria (9) .
IST consisted of horse ATG (Lymphoglobulin, 15 mg/kg/day for 5 days) or rabbit ATG (Thymoglobulin, 2.3 to 5.0 mg/kg/day for 5 days), CSA (6 mg/kg/day for at least more than 6 months), and methylprednisolone (2 mg/kg/day for 5 days) with subsequent halving of the dose every week until discontinuation on day 28. The dose of CSA was adjusted to maintain whole blood concentrations between 150 and 250 ng/ml.
Hematologic response was evaluated at 3 and 6 months after the start of therapy. The definition of complete response (CR), partial response (PR), and relapse are as previously described (1) . A complete response (CR) was defined for all patients as a neutrophil count more than 1.5 × 10 9 /L, a platelet count more than 100 × 10 9 /L, and a hemoglobin level more than 11.0 g/dL. A partial response (PR) was defined as a neutrophil count more than 0.5 × 10 9 /L, a platelet count more than 20 × 10 9 /L, a hemoglobin level more than 80 g/L and no requirement of blood transfusions.
Second-line therapies for non-responders to the first IST depended on the policies of the individual hospitals. To determine predictors of IST response at 6 months, we compared differences in pre-treatment variables between responders and non-responders. The following variables were included in the analysis: etiology, interval between diagnosis and treatment, severity of disease, gender, preparation of ATG, white blood cell counts, reticulocyte counts, and platelet counts. In both univariate and multivariate analyses, differences in ATG preparations were not associated with IST response. Male gender was a significant predictor of better response in multivariate analysis ( Table 3 ).
The OS rates at 2 and 10 years differed significantly between groups and was 96% (95% CI: 93 -98%) and 92% (95% CI: 88 -95%) in the horse ATG group compared with 87% (95% CI: 80 -92%) and 84% (95% CI: 74 -90%) in the rabbit ATG group (p = 0.004). Because 81 of 297 (27%) patients in the horse ATG group and 21 of 158 (13%) patients in the rabbit ATG group underwent SCT as salvage therapy,
we calculated the OS when data were censored at the time of SCT. The transplant-free survival rates at 2 and 10 years also differed significantly between groups and was 99% (95% CI: 95 -99%) and 95% (95% CI: 90 -98%) in the horse ATG group compared with 91% (95% CI: 84 -95%) and 88% (95% CI: 80 -94%) in the rabbit ATG group (p = 0.002).
We assessed prognostic factors associated with OS and transplant-free survival in univariate and multivariate analyses. Rabbit ATG was the only significant adverse factor for both OS and transplant-free survival in the univariate and multivariate analyses (Table 4) .
Clonal evolution to myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) appeared in 13 patients in the horse ATG group and in one patient in the rabbit ATG group. Cytogenetic analysis at the time of evolution showed the following abnormalities: monosomy 7 (n = 7), trisomy 8 (n = 2), trisomy 8 and del (7) (n = 1), monosomy X (n =1), ins (1;?)(q21;?) (n = 1), and t(3;3)(q21;q26) (n = 1) in the horse ATG group. In the rabbit ATG group, only one patient evolved into MDS with normal karyotype. The evolution to clinical paroxysmal nocturnal hemoglobinuria (PNH) was rare: only 3 patients developed clinical PNH [horse ATG (n = 2) and rabbit
The cumulative incidence of clonal evolution at 2 years and 10 years, including both MDS/AML and PNH, was not significantly different between two groups, 4%
(95% CI: 2 -7%) and 6% (95% CI: 4 -10%) in the horse ATG group and 0% (95% CI:
0 -0%) and 5% (95% CI: 1 -19%) in the rabbit ATG group (p = 0.2). However, we must be aware that median follow-up period was much shorter in the rabbit ATG group than in the horse ATG group. On the other hand, the 2 and 10 years cumulative incidence of relapse was significantly higher in the rabbit ATG group (6%, 95% CI: 2 -13% and 15%, 95% CI: 8 -28%) than in the horse ATG group (3%, 95% CI:1 -6% and 7%, 95% CI: 4 -12%) (p = 0.02). Both univariate and multivariate analyses showed that rabbit ATG was the only risk factor for relapse (Table 5 ).
There were 19 deaths in the horse ATG group, including transplant-related toxicity (n = 7), MDS/AML (n = 3), infection within 3 months from IST (n = 2), infection after 3 months from IST (n = 4), hemochromatosis (n = 1), hemolysis (n = 1), and accident (n = 1). Similarly, there were 18 deaths in the rabbit ATG group, including infection within 3 months from IST (n = 4), infection after 3 months from IST (n = 3), bleeding (n = 6), transplant-related toxicity (n = 4), and accident (n = 1).
Discussion
Unlike the prospective NIH study comparing horse ATG and rabbit ATG (5) , our study showed a comparable response rate at 6 months between horse ATG and rabbit ATG, that is, 60% versus 55%, respectively. Although our study has several limitations, including its retrospective design and significant differences in patients' characteristics between groups, the large number of patients and long follow-up period may overcome these drawbacks. A prospective randomized study from the NIH (5) and a retrospective study from Brazil (10) showed significantly lower response rates in the rabbit ATG group.
The response rates at 6 months for rabbit ATG were only 37% and 34%, respectively, which translated into inferior OS rates. However, several other studies showed comparable response rates between horse ATG and rabbit ATG (11) (12) (13) (14) (15) . In the EBMT study, the best total response rate was not significantly different between groups, that is, 67%
versus 60% for horse ATG and rabbit ATG, respectively (6) . Of note, all three retrospective studies from China (11) , and Korea (12) , Japan (13) showed comparative response rates between horse ATG and rabbit ATG, which suggests that ethnicity may be responsible for differences in response rates between studies.
Another issue is the difference in dose of rabbit ATG used in different studies.
In the studies from China (11) , Korea (12) , and Spain (15) , the dose of rabbit ATG was 2.5 mg/kg/day for 5 days, which was lower than the standard dose of rabbit ATG in Europe and United States. In the study from Guagzhou, China, 46 children received rabbit ATG at a dose of 2.5 mg/kg/day for 5 days plus CSA (11) . The response rate was 65% at 6 months, which was comparable to results reported in previous studies with horse ATG (1, 2) .
1 0 responses (16) . Tregs are decreased in SAA patients and an increase in numbers of Tregs may be one of the mechanisms to restore hematopoiesis after ATG therapy (17) . Rabbit ATG, but not horse ATG, induces an expansion of functional Tregs in in vitro cultures (18) . However, in the NIH study, the number of Tregs was much lower in the weeks after treatment with rabbit ATG because of a profound decrease of total CD4 lymphocytes in the rabbit ATG group compared with the horse ATG group (5) . It is interesting to compare the number of Tregs between lower and higher doses of rabbit ATG groups.
Despite the comparative response rates, both OS and transplant-free survival rates were significantly inferior in the rabbit ATG group than the horse ATG group in our study. Multivariate analysis revealed that use of rabbit ATG was the only adverse factor for survival. The incidence of deaths due to infections and bleeding were higher in the rabbit ATG group than the horse ATG group. In the report from Brazil, the excess of deaths observed in the rabbit ATG group occurred mainly within 60 days following administration of ATG. All deaths were caused by infections or bleeding in the report (9) .
In the EBMT report, 11 of 35 patients treated with rabbit ATG patients died of infections (n=9), bleeding (n=1), and transplant-related toxicity (n=1) (6) .
EBV remains latent in B cells after primary infection and is controlled by virus-specific T lymphocytes. Compromising cellular immune responses can put the patient at high risk of Epstein-Barr virus (EBV) reactivation, which can lead to lymphoproliferative disorder (LPD) (19) . Scheinberg et al. reported a series of 78 patients
with AA who received four different IST, of which, the median peak of EBV copy numbers and median duration of polymerase chain reaction (PCR) positivity were significantly higher in the rabbit ATG group than in the other groups (20) . Fortunately, 1 1 progression to clinical disease was not observed after EBV reactivation. They did not recommend routine monitoring of EBV copy numbers. However, recently, a fatal case of EBV LPD was reported in a patient from Japan treated with rabbit ATG as first-line therapy (21) . There is some concern that prolonged T-cell suppression and more active EBV reactivation caused by IST with rabbit ATG might increase the incidence of EBV-LPD.
Based on these findings, intensive supportive care may decrease the mortality and improve the survival rate after rabbit ATG therapy. In fact, among 24 adult patients who received intensive supportive care with levofloxacin, fluconazole, valacyclovir, and granulocyte-colony stimulating factor in the MD Anderson Cancer Center, there were no early deaths in the first 100 days and OS was favorable, 70% at 3 years 12. Dae-Chul Jeong, Nack Gyun Chung, Jae Wook Lee, Pil-sang Jang, Bin Cho, 1 5 globulin and cyclosporine for hepatitis-associated aplastic anemia. Acta haematologica.
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